TATVA CHIN PHARM CHEM LTD (TATVA) financials

TATVA CHIN PHARM CHEM LTD (TATVA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]

Market Cap: ₹4,310Cr.
Current Price: ₹1,841
Stock P/E: 95.0
ROE: 5.29%
ROCE: 6.87%
Book Value: ₹324
Dividend Yield: 0.11%
52W High / Low: ₹2,009/1,044

In Jun 2026, TATVA CHIN PHARM CHEM LTD (TATVA) reported sales ₹147 Cr and net profit ₹10 Cr.

Annual TTM: sales ₹534 Cr, net profit ₹44 Cr.

Shareholding: Promoters 72.02% (Jun 2026), FIIs 3.93% (Jun 2026), DIIs 3.11% (Jun 2026), Public 20.94% (Jun 2026), No. of Shareholders 64,921% (Jun 2026).

TATVA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	81	84	108	109	116	139	133	147
Expenses	76	78	100	94	95	112	106	123
Operating Profit	5	6	8	15	21	27	27	24
OPM %	6%	7%	7%	14%	18%	19%	20%	16%
Other Income	1	0	1	1	1	2	-0	3
Interest	0	0	0	0	1	0	1	2
Depreciation	7	7	7	9	9	9	10	11
Profit before tax	-2	-2	2	7	12	19	15	14
Tax %	-30%	-30%	30%	27%	28%	15%	40%	26%
Net Profit	-1	-1	1	5	9	16	9	10
EPS in Rs	-0.47	-0.50	0.47	2.19	3.82	6.83	3.86	4.47
Raw PDF	—	—	—	—	—	—	—	—

TATVA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	254	291	428	403	379	366	496	534
Expenses	201	226	322	348	312	340	407	436
Operating Profit	53	65	106	55	67	26	90	98
OPM %	21%	22%	25%	14%	18%	7%	18%	18%
Other Income	1	5	11	2	7	3	3	5
Interest	4	4	5	9	7	1	3	5
Depreciation	5	7	8	10	26	28	37	38
Profit before tax	44	59	103	39	42	0	53	60
Tax %	21%	13%	7%	-4%	31%	28%	26%	—
Net Profit	35	51	96	40	29	0	39	44
EPS in Rs	43.51	25.57	43.31	18.26	12.55	0.14	16.71	18.98
Dividend Payout %	-0%	20%	5%	11%	16%	709%	12%	—

TATVA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	20	22	22	23	23	23
Reserves	72	106	142	447	483	702	698	735
Borrowings	77	91	90	120	170	14	36	120
Other Liabilities	31	40	58	87	80	75	65	117
Total Liabilities	187	245	310	676	755	815	823	995
Fixed Assets	67	111	120	160	196	427	529	609
CWIP	6	5	10	51	231	77	24	25
Investments	1	1	1	1	1	11	1	5
Other Assets	114	129	179	464	327	301	269	356
Total Assets	187	245	310	676	755	815	823	995

TATVA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	—	25	19	20	24	103	24	29
Cash from Investing Activity	—	-40	-21	-197	-101	-121	-65	-116
Cash from Financing Activity	—	10	-5	235	38	31	17	79
Net Cash Flow	—	-6	-6	58	-40	13	-25	-8
Free Cash Flow	—	-24	-2	-69	-179	-26	-52	-84
CFO/OP	—	61%	44%	36%	57%	163%	109%	37%

TATVA shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%	72.02%
FIIs	3.33%	3.36%	3.30%	3.26%	3.40%	4.17%	3.81%	3.93%
DIIs	6.83%	6.34%	5.46%	5.11%	3.87%	3.32%	2.99%	3.11%
Public	17.81%	18.27%	19.21%	19.60%	20.72%	20.49%	21.16%	20.94%
No. of Shareholders	79,623	79,009	78,393	76,792	73,331	68,657	66,842	64,921

TATVA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	80	73	113	53	82	66	90	106
Inventory Days	98	165	168	299	249	313	228	268
Days Payable	70	88	116	82	52	96	60	91
Cash Conversion Cycle	109	150	166	269	278	282	258	283
Working Capital Days	46	45	73	72	22	154	139	80
ROCE %	22%	27%	28%	26%	8%	7%	0%	7%

TATVAUpdated 13 Oct 2026, 19:50

Tatva Chin Pharm Chem Ltd

TATVAUpdated 13 Oct 2026, 19:50

Market Cap

₹4,310Cr.

Current Price

₹1,841

High / Low

₹2,009/1,044

Stock P/E

95.0

ROE5.29%

ROCE6.87%

Book Value₹324

Face Value₹10.0

Dividend Yield0.11%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	106	3	86	1	6	12	30	8	3.72
Sep 2023	93	3	72	1	7	12	30	8	3.51
Dec 2023	86	0	74	1	7	7	29	5	1.99
Mar 2024	94	0	80	5	6	12	33	8	3.53
Jun 2024	94	0	86	1	7	2	29	2	0.65
Sep 2024	81	0	76	1	7	-2	-30	-1	-0.47
Dec 2024	84	0	78	0	7	-2	-30	-1	-0.5
Mar 2025	108	0	100	1	7	2	30	1	0.47
Jun 2025	109	0	94	1	9	7	27	5	2.19
Sep 2025	116	1	95	1	9	12	28	9	3.82
Dec 2025	139	0	112	2	9	19	15	16	6.83
Mar 2026	133	1	106	0	10	15	40	9	3.86
Jun 2026	147	2	123	3	11	14	26	10	4.47

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2018	131	3	110	2	3	18	38	11	13.74
Mar 2019	203	4	170	1	4	26	24	20	25.13
Mar 2020	254	4	201	1	5	44	21	35	43.51
Mar 2021	291	4	226	5	7	59	13	51	25.57
Mar 2022	428	5	322	11	8	103	7	96	43.31
Mar 2023	403	9	348	2	10	39	-4	40	18.26
Mar 2024	379	7	312	7	26	42	31	29	12.55
Mar 2025	366	1	340	3	28	0	28	0	0.14
Mar 2026	496	3	407	3	37	53	26	39	16.71
TTM	534	5	436	5	38	60	—	44	18.98

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	72.02%
FIIs	3.93%
DIIs	3.11%
Public	20.94%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	72.02%	4.4%	13.78%	9.79%
Dec 2023	72.02%	4.21%	13.06%	10.72%
Mar 2024	72.02%	3.65%	12.84%	11.49%
Jun 2024	72.02%	3.37%	10.64%	13.97%
Sep 2024	72.02%	3.33%	6.83%	17.81%
Dec 2024	72.02%	3.36%	6.34%	18.27%
Mar 2025	72.02%	3.3%	5.46%	19.21%
Jun 2025	72.02%	3.26%	5.11%	19.6%
Sep 2025	72.02%	3.4%	3.87%	20.72%
Dec 2025	72.02%	4.17%	3.32%	20.49%
Mar 2026	72.02%	3.81%	2.99%	21.16%
Jun 2026	72.02%	3.93%	3.11%	20.94%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2018	8	51	56	29	145	57	10	1	76	145
Mar 2019	8	72	77	31	187	67	6	1	114	187
Mar 2020	8	106	91	40	245	111	5	1	129	245
Mar 2021	20	142	90	58	310	120	10	1	179	310
Mar 2022	22	447	120	87	676	160	51	1	464	676
Mar 2023	22	483	170	80	755	196	231	1	327	755
Mar 2024	23	702	14	75	815	427	77	11	301	815
Mar 2025	23	698	36	65	823	529	24	1	269	823
Mar 2026	23	735	120	117	995	609	25	5	356	995

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2018	—	—	—	—
Mar 2019	—	—	—	—
Mar 2020	25	-40	10	-6
Mar 2021	19	-21	-5	-6
Mar 2022	20	-197	235	58
Mar 2023	24	-101	38	-40
Mar 2024	103	-121	31	13
Mar 2025	24	-65	17	-25
Mar 2026	29	-116	79	-8

Key ratios

Historical financial ratios

Category	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	92	80	73	113	53	82	66	90	106
Inventory Days	134	98	165	168	299	249	313	228	268
Days Payable	132	70	88	116	82	52	96	60	91
Cash Conversion Cycle	94	109	150	166	269	278	282	258	283
Working Capital Days	16	46	45	73	72	22	154	139	80
ROCE %	—	22%	27%	28%	26%	8%	7%	0%	7%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of TATVA CHIN PHARM CHEM LTD (TATVA)?

The reported market capitalisation for TATVA CHIN PHARM CHEM LTD (TATVA) is ₹4,310Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of TATVA?

The current price shown for TATVA CHIN PHARM CHEM LTD (TATVA) on Fincrux is ₹1,841 with a 52-week high/low of ₹2,009/1,044.

What is the P/E ratio of TATVA CHIN PHARM CHEM LTD (TATVA)?

The stock P/E for TATVA CHIN PHARM CHEM LTD (TATVA) is 95.0 on Fincrux, with ROE at 5.29% and ROCE at 6.87%.

What were TATVA latest quarterly results?

For Jun 2026, TATVA CHIN PHARM CHEM LTD (TATVA) reported sales ₹147 Cr and net profit ₹10 Cr (figures in ₹ crore unless noted).

What are TATVA annual sales and net profit?

For TTM, TATVA CHIN PHARM CHEM LTD (TATVA) shows sales of ₹534 Cr and net profit of ₹44 Cr on the Fincrux profit & loss statement.

Who owns TATVA CHIN PHARM CHEM LTD (TATVA)?

Latest shareholding for TATVA CHIN PHARM CHEM LTD (TATVA) on Fincrux: Promoters 72.02% (Jun 2026), FIIs 3.93% (Jun 2026), DIIs 3.11% (Jun 2026), Public 20.94% (Jun 2026), No. of Shareholders 64,921% (Jun 2026).

Where can I find TATVA CHIN PHARM CHEM LTD (TATVA) financials?

TATVA CHIN PHARM CHEM LTD (TATVA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show TATVA balance sheet and cash flow?

Yes. The TATVA CHIN PHARM CHEM LTD (TATVA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 19:50